Importance Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-
related peptide (CGRP), is one of a novel class of new medicines for migraine prevention …

Importance Migraine is a disabling neurological disease characterized by severe headache
attacks. Treatment options reduce migraine frequency for many patients, but adverse effects …

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-
related peptide, used for migraine prevention. Methods A global, double-blind, 6-month …

Background Many patients who require migraine preventive treatment have not been able to
tolerate or have not responded to multiple previous preventive medications. We aimed to …

Introduction There have been no prior trials directly comparing the efficacy of different
calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are …

Objective We examined the efficacy and safety of galcanezumab after treatment cessation in
randomized double‐blind, placebo‐controlled, migraine prevention studies (EVOLVE‐1; …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to
calcitonin gene-related peptide, has demonstrated a significant reduction in monthly …

Objective To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal
antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment …

Background Maintenance of effect following treatment with galcanezumab compared to
placebo in adult patients with episodic or chronic migraine was evaluated. Methods In 2 …

Introduction Acute medication overuse is prevalent in patients with migraine. Methods In
three phase 3, double-blind, randomized, placebo-controlled studies, patients with episodic …